



April 16, 2026

<b>To,</b> <b>Listing Department,</b> <b>BSE Limited</b> <b>Phiroze Jeejeebhoy Towers,</b> <b>Dalal Street,</b> <b>Mumbai – 400 001</b> <b>Ref: BSE Scrip Code: 544497</b>	<b>To,</b> <b>The National Stock Exchange of India</b> <b>Ltd.</b> <b>The Listing Department</b> <b>Exchange Plaza,</b> <b>Bandra – Kurla Complex,</b> <b>Mumbai – 400051,</b> <b>NSE Scrip Code: AHCL</b>
--	---

**Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).**

Dear Sir/Madam,

With reference to the captioned subject, we would like to inform you that pursuant to the approval of the Board of Directors of the Company at its meeting held today on April 16, 2026, the Company has entered into a share purchase agreement (“SPA”) dated April 16, 2026 with Remember India Health Links Private Limited (“**Target Company**”) and its majority shareholders for acquisition of 63.98% (Sixty Three Point Nine Eight only) shareholding of the Target Company from such shareholders, in accordance with and subject to the terms and conditions as set out in the SPA.

Pursuant to the terms of the SPA and upon fulfilment of conditions precedent contained in the SPA, Purchaser being the Company will acquire management and control of the Target Company, and upon completion of such acquisition, the Target Company will become subsidiary of the Company.

The Annexure contains details pursuant to Schedule III of the Listing Regulations and additional details as required under the SEBI Master Circular for compliance with the provisions of the Listing Regulations by listed entities, bearing ref. no. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026.

You are requested to take the above information on your record.

Thanking You.

**For ANLON HEALTHCARE LIMITED**

**PUNITKUMAR RASADIA**  
**MANAGING DIRECTOR**  
**DIN: 06696258**

---

**ANLON HEALTHCARE LIMITED**

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: [info@anlonhealthcare.com](mailto:info@anlonhealthcare.com) | [www.anlon.in](http://www.anlon.in)



#### ANNEXURE-A

#### Details required under Regulation 30 of SEBI LODR read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155, dated November 11, 2024

Sr No.	Particulars	Description
1	Name of the target entity, details in brief such as size, turnover etc.;	<p><u>Name:</u> Remember India Health Links Private Limited ("Target Company") (CIN: U24246GJ2020PTC118900) is an Indian private limited company, incorporated on December 17, 2020.</p> <p><u>Brief details:</u> The Target Company is <i>inter alia</i> engaged in the business of manufacturing, processing, producing, packing, selling, blending, making and dealing in all kinds and varieties of pharmaceutical finished products/formulations such as tablets, capsules etc.</p> <p><u>Turnover:</u> Rs.83.08 Lakh as on 31.03.2025</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No
3	Industry to which the entity being acquired belongs;	Pharmaceuticals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	<p>The primary objective of the proposed acquisition is to transform ourselves from an API manufacturer to a complete pharmaceutical provider. Through this acquisition, we will expand our presence across the pharmaceutical value chain by moving beyond drug substances (APIs) into finished dosage formulations (FDFs), while also gaining access to more than 30 dossiers relating to finished dosage formulations.</p> <p>The impact of the proposed acquisition is expected to extend across operational, financial and regulatory dimensions. In particular, it is expected to facilitate integration</p>

#### ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: [info@anlonhealthcare.com](mailto:info@anlonhealthcare.com) | [www.anlon.in](http://www.anlon.in)



		of quality control processes, strengthen our financial profile, and enhance our market positioning from a B2B ingredient supplier to a broader pharmaceutical and healthcare platform with presence in domestic and international retail and hospital markets.								
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable								
6	Indicative time period for completion of the acquisition;	The proposed acquisition is subject to completion of certain condition precedents under the SPA and is expected to be completed at the earliest but within 4 to 5 months from the date of signing of the SPA or by such other timelines as may be mutually agreed between the parties.								
7	Consideration - whether cash consideration or share swap or any other form and details of the same;	The consideration would be paid in cash.								
8	Cost of acquisition and/or the price at which the shares are acquired;	<p><u>Cost of acquisition:</u> Rs.5,38,12,800/-</p> <p><u>Price at which shares are acquired:</u> 1,11,00,000 equity shares at a price of Rs. 4.848/- each, aggregating Rs.5,38,12,800/-.</p>								
9	Percentage of shareholding / control acquired and / or number of shares acquired;	<p><u>Percentage of shareholding acquired:</u> 63.98% of the Target Company</p> <p><u>Control acquired:</u> Yes</p> <p><u>Number of shares acquired:</u> 1,11,00,000 equity shares of the Target Company</p>								
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p><u>Brief background:</u> Please refer (1) above.</p> <p><u>Country in which the acquired entity has presence:</u> India</p> <p><u>Turnover for the last 3 years:</u></p> <table border="1"> <thead> <tr> <th>Financial Year</th> <th>Amt. in Lakh</th> </tr> </thead> <tbody> <tr> <td>2022-23</td> <td>Rs.98.65</td> </tr> <tr> <td>2023-24</td> <td>Rs.169.83</td> </tr> <tr> <td>2024-25</td> <td>Rs.83.08</td> </tr> </tbody> </table>	Financial Year	Amt. in Lakh	2022-23	Rs.98.65	2023-24	Rs.169.83	2024-25	Rs.83.08
Financial Year	Amt. in Lakh									
2022-23	Rs.98.65									
2023-24	Rs.169.83									
2024-25	Rs.83.08									

**ANLON HEALTHCARE LIMITED**

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in